SGLT2 Inhibitors Explained: Telomeres, Senescence & Longevity Research

SGLT2 inhibitors were developed to lower blood sugar in type 2 diabetes — but a growing body of research suggests they may influence some of the actual hallmarks of aging, including cellular senescence and telomere length. Brandon and Rich break down the mechanism, a 2024 mouse study on senescent cell clearance, and a 2025 human trial showing telomere lengthening — plus what this means beyond glycemic control. Timestamps: 00:00 – Intro: what's new with SGLT2 inhibitors 04:01 – Mechanism: how SGLT2 inhibitors work 18:36 – Cellular senescence explained 21:32 – 2024 study: SGLT2 inhibition clears senescent cells 28:32 – Telomere biology and the 2025 human trial 40:07 – Better ways to track biological aging 46:44 – Summary, risks, and actionable takeaways Want to explore SGLT2 inhibitors for your own health? Get started with Healthspan: https://www.gethealthspan.com/treatments/sglt2-metabolic-protocol?zp_type=product&zp_slug=sglt2-metabolic-protocol #SGLT2Inhibitors #Empagliflozin #Dapagliflozin #Canagliflozin #Bexagliflozin #Anagliflozin #CellularSenescence #TelomereLength #HallmarksOfAging #MetabolicHealth #A1CReduction #BiologicalAge